BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302571% above fair value
$413.26+1.97 (+0.48%)
Close on Nov 17, 2026Market cap $46.99BP/E 73.9Yield –
BeOne Medicines operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
BeOne Medicines's operating cash flow for the twelve months ending Jun 30, 2026 was $1.48B, up 159.8% year over year. For fiscal 2025 it was $1.13B. The highest annual figure on record is $1.13B in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.13B | – |
| FY2024 | Dec 31, 2024 | -$140.63M | – |
| FY2023 | Dec 31, 2023 | -$1.16B | – |
| FY2022 | Dec 31, 2022 | -$1.50B | – |
| FY2021 | Dec 31, 2021 | -$1.30B | – |
| FY2020 | Dec 31, 2020 | -$1.28B | – |
| FY2019 | Dec 31, 2019 | -$750.27M | – |
| FY2018 | Dec 31, 2018 | -$547.72M | -4395.1% |
| FY2017 | Dec 31, 2017 | $12.75M | – |
| FY2016 | Dec 31, 2016 | -$89.51M | – |
| FY2015 | Dec 31, 2015 | -$39.84M | – |
| FY2014 | Dec 31, 2014 | -$8.69M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $462.82M | +75.6% |
| Q1 FY2026 | Mar 31, 2026 | $201.34M | +356.7% |
| Q4 FY2025 | Dec 31, 2025 | $417.35M | +455.3% |
| Q3 FY2025 | Sep 30, 2025 | $402.55M | +113.7% |
| Q2 FY2025 | Jun 30, 2025 | $263.60M | – |
| Q1 FY2025 | Mar 31, 2025 | $44.08M | – |
| Q4 FY2024 | Dec 31, 2024 | $75.16M | – |
| Q3 FY2024 | Sep 30, 2024 | $188.37M | – |
| Q2 FY2024 | Jun 30, 2024 | -$95.59M | – |
| Q1 FY2024 | Mar 31, 2024 | -$308.57M | – |
| Q4 FY2023 | Dec 31, 2023 | -$221.64M | – |
| Q3 FY2023 | Sep 30, 2023 | -$78.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$293.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$563.78M | – |
| Q4 FY2022 | Dec 31, 2022 | -$318.19M | – |
| Q3 FY2022 | Sep 30, 2022 | -$561.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$379.96M | – |
| Q1 FY2022 | Mar 31, 2022 | -$236.56M | -289.1% |
| Q4 FY2021 | Dec 31, 2021 | -$507.84M | – |
| Q3 FY2021 | Sep 30, 2021 | -$495.71M | – |
| Q2 FY2021 | Jun 30, 2021 | -$420.27M | – |
| Q1 FY2021 | Mar 31, 2021 | $125.10M | – |
| Q4 FY2020 | Dec 31, 2020 | -$332.33M | – |
| Q3 FY2020 | Sep 30, 2020 | -$346.24M | – |
| Q2 FY2020 | Jun 30, 2020 | -$262.94M | – |
| Q1 FY2020 | Mar 31, 2020 | -$341.94M | – |
| Q4 FY2019 | Dec 31, 2019 | -$267.18M | – |
| Q3 FY2019 | Sep 30, 2019 | -$265.01M | – |
| Q2 FY2019 | Jun 30, 2019 | -$46.10M | – |
| Q1 FY2019 | Mar 31, 2019 | -$171.98M | – |
| Q4 FY2018 | Dec 31, 2018 | -$193.89M | -306.8% |
| Q3 FY2018 | Sep 30, 2018 | -$132.19M | -2102.8% |
| Q2 FY2018 | Jun 30, 2018 | -$117.14M | – |
| Q1 FY2018 | Mar 31, 2018 | -$104.50M | – |
| Q4 FY2017 | Dec 31, 2017 | $93.75M | – |
| Q3 FY2017 | Sep 30, 2017 | $6.60M | – |
| Q2 FY2017 | Jun 30, 2017 | -$51.89M | – |
| Q1 FY2017 | Mar 31, 2017 | -$35.71M | – |
| Q4 FY2016 | Dec 31, 2016 | -$26.14M | – |
| Q3 FY2016 | Sep 30, 2016 | -$24.28M | – |
See a number that looks wrong?